MELBOURNE, Australia — August 19, 2025 — Leads & Copy — Propanc Biopharma, Inc. (Nasdaq: PPCB) closed an underwritten public offering of 1,000,000 shares of its common stock at $4.00 per share, raising gross proceeds of $4 million before deductions. Trading commenced on the Nasdaq Capital Market on August 15, 2025, under the ticker “PPCB”.
The underwriter has a 45-day option to purchase up to 150,000 additional shares. D. Boral Capital LLC and Craft Capital Management LLC acted as book running managers. Brunson Chandler & Jones PLLC served as counsel to Propanc, and Sichenzia Ross Ference Carmel LLP acted as counsel to the underwriters.
Propanc Biopharma is developing cancer treatments targeting recurring and metastatic cancer by using pancreatic proenzymes to eradicate cancer stem cells. The company’s therapy is based on the science that pancreatic enzymes could represent the body’s primary defense against cancer.
James Nathanielsz
+61-3-9882-0780
info@propanc.com
Source: Propanc Biopharma, Inc.
